Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects sales to fall by a lot more than analysts were projecting.
In a surprise move, the Danish drugmaker
NVO announced its fourth-quarter results a day early. Within the results, the company said it expects 2026 adjusted sales growth, which excludes certain nonrecurring items, to fall by 5% to 13% from 2025 levels. That came as a surprise to investors, as the current average analyst estimate compiled by FactSet for 2026 sales implies just a 3.5% decline.
Novo Nordisk’s stock tumbles as drugmaker lays out case for declining sales in 2026
Published:
Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects sales to fall by a lot more than analysts were projecting.
In a surprise move, the Danish drugmaker
NVO announced its fourth-quarter results a day early. Within the results, the company said it expects 2026 adjusted sales growth, which excludes certain nonrecurring items, to fall by 5% to 13% from 2025 levels. That came as a surprise to investors, as the current average analyst estimate compiled by FactSet for 2026 sales implies just a 3.5% decline.
Share this:
Related